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Abstract
Liver transplantation has been developed in Mainland China for about 40 years, 
from clinical trials to maturity. Its number has become the second in the world, 
its quality is also in line with the international level, and the source of donors has 
gradually transitioned to donation after citizen’s death (DCD). This chapter is 
aimed to elaborate the liver transplant work in China from the history and current 
status of liver transplantation, the main operating methods, major indications, 
donor maintenance and donor quality assessment, postoperative major complica-
tions, and application of immunosuppressive agents to the postoperative follow-up. 
Liver transplantation is a meaningful and challenging work currently in China; all 
the Chinese transplant surgeons and scholars are devoting themselves to this work 
in order to give more effective help to the patients.
Keywords: liver transplantation, Mainland China, DCD, piggyback liver 
transplantation, donor quality assessment, liver transplant indications, HBV, liver 
transplant complications, immunosuppressant, follow-up
1.  The developing history and current status of liver transplantation  
in China
Since the first clinical trial of liver transplantation in Mainland China in 1977, it has 
been more than 40 years. During this period, China’s liver transplantation has expe-
rienced ups and downs and finally developed from immature to mature. Liver trans-
plantation has been recognized as the only effective treatment for various end-stage 
liver diseases. The number of liver transplant cases in China ranks second in the world, 
ranking behind the United States. Its rapid development has attracted the attention of 
the world, and it has also exposed many problems that need to be solved [1].
The development of liver transplantation in China has gone through the follow-
ing stages:
(1) The initial trial stage (1977–1983). In 1977, Shanghai Ruijin Hospital and Wuhan 
Tongji Hospital started the clinical liver transplantation in China. From 1977 to 
1983, 57 liver transplants were carried out nationwide, but because the liver trans-
plantation indications at that time were mainly advanced primary liver cancer, 
the curative effect was poor, and most patients died 3 months after surgery. Ten 
years later (1983–1993), China’s liver transplantation was basically at a standstill.
(2) Re-development stage (1993–1997). With the continuous entry of new 
immunosuppressants into China, the continuous improvement of surgical 
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techniques and perioperative management, and the continuous strengthen-
ing of international exchanges and cooperation, China’s liver transplantation 
finally re-emerged in the 1990s.
(3) Rapid development stage (1997–2005). This is the main stage of liver trans-
plantation development in China, and the main performance is as follows: 
(1) the number of liver transplants in mainland China has increased year by 
year. From 16 cases in 1997 to 100 cases in 1999, there were 200 cases of liver 
transplantation in 2000. By 2005, 3300 cases of liver transplantation were 
implemented. (2) The units and regions for liver transplantation have also 
increased year by year. More than 300 hospitals across the country have carried 
out liver transplantation. (3) Liver transplantation is diversified, from tradi-
tional classic liver transplantation to piggyback liver transplantation, ectopic 
liver transplantation, partial liver transplantation, split liver transplantation, 
and living donor liver transplantation. (4) The postoperative management 
level is continuously improved, the application of immunosuppressive agents 
is more individualized and diverse, and the survival rate of recipients is 
significantly improved. The 1-year survival rate after liver transplantation was 
80.5%, and the 5-year survival rate was 65.9%. Liver transplantation technol-
ogy and clinical efficacy are close to international standards [2]. In 2006, the 
Ministry of Health conducted an access work for organ transplant medical 
institutions, and China’s liver transplantation entered the stage of clinical 
normative development. Liver transplantation is gradually incorporated into 
the legal management. The medical institutions that are admitted are mainly 
strong medical institutions that have mature liver transplantation technology 
and talented echelons. Taking the service area and scope into account, the 
admitted liver transplant medical institutions are mainly concentrated in the 
affiliated hospitals of the provincial capital universities in the big cities, which 
further guarantee the quality, safety, and management of transplants [3]. In 
2007, China’s first “Human Organ Transplantation Regulations” was officially 
implemented, and the Ministry of Health also issued relevant supporting 
regulations, marking a crucial step in the legalization and standardization 
of China’s organ transplantation [4]. In February 2005, the China Liver 
Transplant Registration Network was established. The system was supported 
by the University of Hong Kong with the support of the Ministry of Health. 
In May 2008, the China Liver Transplant Registration Network was officially 
authorized by the Ministry of Health to further cover the 80 admitted liver 
transplantation centers [5]. China Liver Transplant Registration Network has 
been upgraded from scientific voluntary registration to administrative manda-
tory registration, becoming the standardized management system for liver 
transplantation in China. China Liver Transplant Network has collected more 
than 12,000 cases of domestic liver transplant patients. By the end of 2008, 
China had implemented 14,600 liver transplants. By August 10, 2009, China 
had implemented 16,158 liver transplants until July 22, 2010. The Chinese 
transplant network registered 18,180 liver transplants [6].
(4) DCD (organ donation after citizen’s death) Liver transplantation stage (2010–
present) in 2010. China gradually began trial of DCD for liver transplantation, 
with 11 provinces including Zhejiang, Yunnan, Hubei, and Hunan as the first 
batch of pilots. The DCD was vigorously promoted and achieved good results. 
Summary after the completion of the pilot work: as of July 1, 2013, a total of 
906 DCD donors donated nationwide, and 2469 organs were donated, includ-
ing 746 livers. The above data show that although the Chinese DCD work 
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started late, in the future it is the most potential source of organs [7]. Under 
the vigorous promotion of the Ministry of Health and the Red Cross Society, 
DCD work began to be promoted nationwide in 2012, and the construction 
of relevant laws and regulations also steadily advanced. In October 2012, in 
order to better implement the “Human Organ Transplant Regulations” and 
actively promote the Chinese organ donation work, the Ministry of Health 
formulated the “Management Methods for the Acquisition and Distribution 
of Human Organs in China” and established the “China Organ transplant 
response system” (OTRS). Through the application of this system, we wish to 
improve the matching degree of organs, reduce or prevent waste of resources, 
strive to achieve the traceability of each distributed organ, and eliminate the 
interference of human and subjective factors to ensure the principle of “fair-
ness, openness, and justice” [8]. In 2010, DCD liver transplantation accounted 
for only 1.38% of the total, and in 2013, it has increased significantly to 26.02% 
[9], and by 2015, it has exceeded 80% [10]. China has completely banned the 
use of organs in the judicial channel since 2015. DCD donor China has become 
the main source of donors for organ transplantation in China. In 2017, 4732 
cases of liver transplantation were performed in China, including 4138 cases of 
DCD liver transplantation, which was 26.43% higher than that of 2016 (3273 
cases). The data show that the survival rates of liver transplantation in China at 
1, 3, and 5 years are 84, 75, and 71%, respectively. The Chinese organ trans-
plantation has entered the DCD era [11].
Although China’s organ transplants have developed rapidly, they have also 
achieved many achievements and showed the characteristics of China, but they also 
exposed some problems.
(1) Problems faced by liver transplantation for liver cancer.
China is a big country with hepatitis B. The HBV carrying rate is about 10% 
in the national population. As the terminal end of the development chain of 
hepatitis-cirrhosis-hepatocarcinoma, the high incidence of liver cancer in 
China is inevitable. China’s liver cancer patients account for more than half of 
the world’s liver cancer patients, and 318,000 new liver cancer patients occur 
in China each year. With the continuous improvement of the medical insur-
ance system, China has the world’s largest transplant recipient group, liver 
cancer liver transplantation once accounted for about 44% of China’s total 
liver transplant [5]. It is urgent to formulate the staging criteria and surgical 
adaptation of liver cancer liver transplantation in accordance with China’s 
national conditions as soon as possible. At the same time, how to combine 
immunosuppressive agents with antiliver disease and antihepatitis virus treat-
ment is the main problem faced by Chinese transplant experts [12].
(2) Problems faced by the DCD era.
The development of DCD donors has effectively alleviated the problem of 
donor shortages in China, and has also led to the complete abolition of judicial 
source donors. However, the current organ donation rate in China is still very 
low. In 2010, it was only 0.03 cases/million population. In 2015, it was 2.03 
cases/million population, and in 2016, it was 2.98 cases/million population 
[13]. Although the growth is relatively fast, there is still a huge growth poten-
tial. This requires all levels of government in China to increase the propaganda 
of donations, and at the same time increase the staff of organ donation to find 
and report the information of potential donors in a timely manner. At the 
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same time, a complete organ donation process must be developed to ensure the 
smooth implementation of the donation.
(3) Basic and clinical research related to transplantation needs to be strengthened.
Organ transplantation is a multidisciplinary and interdisciplinary profession. 
Only by strengthening relevant basic and clinical research, can we better 
protect organ quality and provide better postoperative management and 
monitoring of patients [14].
(4) The relevant laws and regulations on transplantation have yet to be perfected.
The current regulations on organ transplantation in China are mainly based 
on “the Interim Provisions on the Clinical Application Management of 
Human Organs Technology” issued in July 2006 and the “Human Organ 
Transplantation Regulations” promulgated by the State Council in March 
2017. However, with the development of transplantation and the advent of the 
DCD era, more completed legal and ethical systems and management norms 
are needed to provide legal protection and policy support for the healthy and 
orderly development of organ transplantation in China.
China’s clinical liver transplantation has entered a critical period of simultaneous 
hopes and challenges, and Chinese liver transplant experts are constantly working 
hard to make liver transplantation a better way for patients with liver disease.
2. Quality assessment of liver grafts
In China, liver grafts used for transplantation are mainly from DCD (organ 
donation after citizen’s death), which includes DBD, DCD, DBCD, and living related 
donor. Here, we discuss the quality assessment of liver grafts from DCD. The qual-
ity of transplant liver is an important factor affecting the short-term and long-term 
effects of transplantation. Donated liver assessment mainly includes donor’s general 
information, medical history, general condition and intervention, laboratory results, 
etc. and specific items are listed in Table 1 [15]. Every case is evaluated dynamically, 
including at least one preliminary evaluation and final assessment prior to liver har-
vest. Donor age, hepatic steatosis, warm and cold ischemia time, the risk of infection 
and tumor, hypernatremia, etc. are risk factors affecting the quality of liver grafts.
2.1 Donor age
It is generally believed that elderly donors often have higher opportunity of 
getting arteriosclerosis, hepatic steatosis, and tumor, which are risk factors affect-
ing the quality of liver. Therefore, age is an important factor in the evaluation of 
liver grafts, and usually, donor age > 50 years is considered a contraindication to the 
use for transplantation. However, as the progression of liver transplantation and 
the relatively expanded need for liver grafts, liver grafts from these elderly donors 
can also be used with rigorous assessment, especially in the case of ensuring a short 
warm and cold ischemia time [16–18].
2.2 Hepatic steatosis
Hepatic steatosis is an important factor affecting liver function after transplanta-
tion; hence, the classification and the grading of hepatic steatosis are extremely 
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pivotal. According to the histology classification, hepatic steatosis is mainly divided 
into macrovesicular steatosis, which is considered to be a more dangerous one, 
and microvesicular steatosis, which is generally regarded as being reversible. For 
microvesicular steatosis liver grafts, even though the lesion is severe, they can still 
be used. For macrovesicular steatosis liver grafts, if the lesion is more than 50%, 
it is considered to be a taboo for transplantation [19, 20]. At present, the methods 
for evaluating fatty liver graft mainly relies on the judgment of organ harvesting 
surgeon, and rapid frozen biopsy of liver grafts [21, 22]. The research toward the use 
of imaging methods such as ultrasound, CT, MRI, and metabonomics in the assess-
ment of liver steatosis is launched and their efficiency still need to be verified [23].
2.3 Warm and cold ischemia injury
Warm ischemic injury caused by hypotensive and hypoxic perfusion process 
is one of the most important features of liver grafts. Long-term ischemia can 
increase the risk of primary nonfunction and biliary complications; thus, the 
time of warm ischemia is an important factor in evaluating the quality of liver. 
In addition, cold ischemia time > 8 hours is also a risk factor of liver trans-
plantation. It has been reported that the incidence of liver failure after trans-
plantation increases by 8% for every 1 hour after cold ischemia time > 6 hours. 
Therefore, during the process of liver acquisition, in order to improve the 
quality of grafts, the operation and transportation time should be shortened as 
much as possible [18].
Category Item Category Item
General information of 
donor
Gender Laboratory tests Blood routine
Age Urine routine
Blood type Fecal routine
Height Liver function
BMI Blood lipids
Medical history Primary disease (cause of 
death)
Blood sugar
ICU stay days Blood electrolytes
Past history Coagulation function
Family history HIV
General condition and 
intervention
Vital signs Hepatitis virus
Urine volume Syphilis tests
Mechanical ventilation Tumor markers




Other Judgment during 
harvesting operation
Warm and cold ischemia 
time




Assessment content of liver grafts.
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2.4 Hepatitis virus infection
It is mainly hepatitis B virus prevailing in China. The main route of HBV infec-
tion in liver transplant recipients is through liver grafts. Liver graft from the donor 
who is in active period of hepatitis virus infection or has developed hepatitis virus-
related liver fibrosis should not be used. For HBV-positive grafts, they can still be 
used to recipients who are selected rationally, get prophylactic antiviral therapy and 
the treatment of HBV immunoglobulin [18, 19]. HCV infection is not common in 
China. HCV-positive liver grafts can be used to recipients who need transplantation 
urgently, and they need anti-HCV therapy after surgery.
2.5 Tumor
For donors who have malignant tumors or tumor history, whether the liver can 
be used for transplantation remains controversial, and the transfer risk of tumor 
cannot be properly assessed. It is generally believed that the incidence of donor-
related tumor and the resulting mortality are very low. However, the current view 
is that the liver from donors who have malignant tumor history should be selected 
carefully because some malignant tumors have unpredictable possibilities of recur-
rence and metastasis [19].
2.6 Hypernatremia
Hypernatremia (serum sodium >155 mmol/L) in donors is an important factor 
affecting the prognosis of liver transplantation. Studies have shown that hyper-
natremia affects the function of transplant organs and increases the risk of liver 
failure after transplantation, whose mechanism may be related to cell swelling, 
increased osmotic pressure, and reperfusion injury caused by hypernatremia. This 
adverse effect can be reduced by effectively correcting the blood sodium concentra-
tion [18].
2.7 Liver preservation
The effect of liver preservation affects the quality of grafts. At present, there are 
two methods of liver storage, which are static cold storage (SCS) and mechanical 
perfusion (MP). SCS is the most widely used method, and UW liquid, HTK liquid 
and Celsior liquid are the most popular preservation liquids. The ideal time for cold 
storage is less than 8 hours, and in clinical practice, the preservation time gener-
ally does not exceed 12–15 hours. MP can continuously infuse the organ’s intrinsic 
vascular system to deliver nutrient, achieve organ preservation, and repair simulta-
neously, having great value in prolonging the time of liver preservation and improv-
ing organ quality. Besides, MP can monitor liver function, bile secretion and other 
indicators dynamically during storage and transportation, and evaluate the quality 
of donated liver, showing important clinical application prospects [24, 25].
3. Donor liver procurement and benchwork surgery
3.1 Donor liver procurement
Since there is still no law about brain death, at the present stage in China, the 
sources of liver are DCD and living-related donation. Here, we only talk about the 
DCD donor liver procurement.
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It is recommended in most centers the “rapid cold perfusion and en-bloc 
liver-kidney procurement” technique [26]. Core temperature of the liver can be 
decreased rapidly to 0–4°C by double perfusion from the hepatic artery (aortic 
cannulation) and the portal vein (superior mesenteric vein cannulation). This 
technique also prevents accidental injuries to the hepatic hilar structures.
Following administration of 30,000 IU or 300 IU/Kg of heparin, expeditious 
access to the abdominal cavity is obtained through a midline incision from the 
xiphoid to the pubic symphysis. The abdominal aorta and inferior vena cava (IVC) 
are dissected and cannulated, and the cold flush (0–4°C normal saline) is initiated 
immediately. Superior mesenteric vein is isolated and cannulated at the root of 
small bowel mesentery followed with perfusion. Ice and slush are packed around 
the liver and kidneys, and subsequent dissection is carried out after completion of 
cold perfusion (Figure 1).
The liver is mobilized by dividing the round ligament, falciform, left triangular, 
and gastrohepatic ligaments. The hepatoduodenal ligament, posterior perito-
neum nearby and the adhesions between the head of pancreas and duodenum 
are dissected with modified Kocher maneuver; the common bile duct is exposed 
and transected at the inferior margin of pancreas. The whole colon, stomach, and 
duodenum are isolated successively; then the bilateral peritoneum are cut open and 
the peritoneal attachments in the retroperitoneal space are divided until the spine. 
The ureters are isolated and transected at the common iliac artery level. After the 
procedure, only the liver, spleen, kidneys, and most part of pancreas are still left 
in the abdominal cavity. The pericardium and diaphragm are incised bilaterally: on 
the left, extending to the esophagus, and on the right, extending posterior the right 
lobe of the liver, adrenal gland, and IVC. The thoracic aorta and IVC are transected 
Figure 1. 
The intubation perfusion of aorta and portal vein.
Surgical Challenges in the Management of Liver Disease
8
Figure 2. 
The trimmed and shaped donor liver.
and the adhesions with the spine are divided until the common iliac artery level. 
The en-bloc liver-kidney-spleen organs cluster can be harvested with the aorta and 
IVC transection just below the cannulas.
Once the multiple-organs cluster is taken out, it must be put into the sterile basin 
filled with 0–4°C organ preservation solution (usually UW solution) immediately. 
Additional perfusion usually is needed in order to eliminate the residual blood and 
sustain the low core temperature of the organs. The posterior wall of the aorta is lon-
gitudinal cut out, and the origins of celiac truck, superior mesenteric artery (SMA) 
and bilateral kidney arteries are exposed. The adhesions between the right kidney, 
adrenal gland, and the hepatic right lobe are divided until the inferior IVC exposed. 
IVC is transected just above the kidney veins level, and aorta is transected below the 
origin of SMA level; the liver and kidneys are separated and packaged respectively.
3.2 Bench surgery
The aim of bench surgery is to remove the unnecessary tissues attached to the 
liver and trim the main vessels and bile duct for a convenient anastomosis. The 
bench should be set up with a suitable sized bowl in which the graft is kept in sterile 
slush ice and UW at 4°C for the duration of the procedure to avoid rewarming.
Firstly, the diaphragm and remaining cardiac muscle are removed from the bare 
area of the liver and the vena cava. Then, the supra- and intrahepatic vena cava are 
skeletonized and all small branches are ligated with silk. The adrenal vein and the 
phrenic veins are tied or over sewn to prevent bleeding upon recirculation.
The skeletonization of the hepatic artery is the most critical step in the bench 
surgery procedure. The dissection starts from the aorta and ends until the gastro 
duodenal artery (GDA) in order not to injure the hepatic lobar vessels. Care is taken 
to identify any aberrant arterial anatomy, which can be present in up to 20% of the 
population [27]. So, every artery and its branches should be isolated until it is iden-
tified that not entering the liver. The most common two variants are a replaced right 
hepatic artery emanating from superior mesenteric artery or a replaced left hepatic 
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artery originating from the left gastric artery. Often the aberrant liver arteries need 
to be reconstructed for anastomosis.
The portal vein is skeletonized up to 1–2 cm below the bifurcation point. 
Surrounding lymphatic tissue is removed, and care is taken not to injure the hepatic 
artery or bile duct.
The pancreas tissues around the lower segment of the common bile duct are 
removed. Do not dissect excessively the tissues between the bile duct and the 
hepatic artery in order to preserve the blood supply of the bile duct.
A perfusion-giving set with cold UW should be set up to perfuse the liver and 
also to check the integrity of the portal vein and arterial tree, once the graft has 
been prepared for implantation (Figure 2).
4. Surgical methods of recipient liver transplantation
Surgical methods of recipient liver transplantation include two main categories: 
orthotopic liver transplantation and ectopic liver transplantation [28]. At present, 
transplant centers in China basically use orthotopic liver transplantation. Orthotopic 
liver transplantation is divided into classic orthotopic liver transplantation, piggy-
back orthotopic liver transplantation, reduced-size liver transplantation, split liver 
transplantation, and auxiliary liver transplantation according to different surgical 
methods. The above procedures are applied in the Chinese transplant centers.
4.1 Classical orthotopic liver transplantation
4.1.1 Diseased liver resection
A curved cut under the regular costal edge or “Mercedes-Benz” logo shape 
incision has been made firstly, then dissecting the first hepatic portal dissecting the 
hepatic artery, separating the common bile duct, and finally separating the portal 
vein [29]. The inferior vena cava is then exposed. The posterior inferior vena cava 
can be quickly and safely separated from the posterior peritoneum [30].
4.1.2 Extracorporeal portal
The nonhepatic venous bypass technique can reduce the congestion of the portal 
system and can solve the problem of blood return in the intestine and inferior vena 
cava during the nonhepatic period [31, 32]. As the surgical techniques become more 
and more skilled, the anastomosis time is shortened. At present, most transplant cen-
ters in China have adopted nontransfer liver transplantation technology [33]. However, 
for patients with severe hepatorenal syndrome, gastrointestinal bleeding, and cardiac 
insufficiency before surgery, extracorporeal portal bypass technology will still benefit.
4.1.3 Graft implantation
The portal vein and two inferior vena cava were clamped in turn, to avoid 
vascular torsion, and the blood vessels were cut off near the liver to remove the 
diseased liver. The suprahepatic inferior vena cava the infrahepatic inferior vena 
cava and the portal vein were sequentially anastomosed with 3-0, 4-0, and 5-0 
Prolene sutures. The anastomosis was performed by two-point continuous valgus 
suture. Precautions of inferior vena cava anastomosis: A. The inferior vena cava 
of the recipient and the donor cannot be kept too long or too short; otherwise, 
Surgical Challenges in the Management of Liver Disease
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Figure 3. 
The classical orthotopic liver transplantation.
the inferior vena cava will be folded or stretched, and the inferior vena cava 
hypertension or bleeding will be caused. B. The recipient’s suprahepatic inferior 
vena cava cannot be reversed; otherwise, it will cause poor blood flow in the 
inferior vena cava. C. The suture cannot be pulled too tightly to avoid damage 
to the intima form artificial stenosis, and even lead to Budd-Chiari syndrome. 
Precautions of hepatic portal vein anastomosis: A. Donor and recipient’s portal 
vein should be kept proper. B. The difference between the size of the portal vein 
of the donor and the recipient should not be too large, otherwise. C. The tension 
of the anastomosis needs to be appropriate. When the suture is completed, the 
“widening factor” of the portal vein should also be retained. The transplanted 
liver blood flow is then opened. The hepatic artery was reconstructed with a 7-0 
Prolene suture, and the hepatic artery was opened. Successful hepatic artery 
reconstruction is critical to the function of the transplanted liver and the influ-
ence of bile duct. There is a variety of suturing methods: A. Separate the hepatic 
artery, the gastro duodenal artery and the common hepatic artery, and the 
three confluences were trimmed as a hornline, which was anastomosed with the 
donor’s common hepatic artery. B. When the gastroduodenal artery is relatively 
large, the donor’s celiac trunk artery can be anastomosed at the junction of the 
recipient’s gastroduodenal artery and the proper hepatic artery. C. If there is 
an anatomic abnormality in the hepatic artery of the donor, the hepatic artery 
should be trimmed, shaped, and then anastomosed with the recipient’s hepatic 
artery. D. When the recipient’s hepatic artery has an anatomic abnormality, the 
donor’s celiac trunk artery can be directly anastomosed to the abdominal aorta 
above the recipient’s celiac trunk artery. Finally, the bile duct was reconstructed 
with a 6-0 or 7-0 Prolene suture. T tube is drawn through the recipient’s common 
bile duct. If the recipient’s common bile duct is very small, it is recommended to 
perform bile duct jejunum Roux-en-Y anastomosis. The graft gallbladder was then 
removed [34–36] (Figure 3).
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4.2 Piggyback liver transplantation
Piggyback liver transplantation, different from the classical liver transplanta-
tion, is that the infrahepatic inferior vena cava is not necessary to be anastomosed, 
which thereby is clamped, and the suprahepatic inferior vena cava of the donor liver 
is anastomosed directly to the recipient’s hepatic vein or laterally to the recipient’s 
inferior vena cava [37, 38]. This procedure simplifies the operation of donor liver 
implantation, and only partially blocks the inferior vena cava during operation. It 
has little effect on hemodynamics in patients in nonhepatic phase, does not require 
venous bypass, and has less renal damage. However, this traditional piggyback 
liver transplantation procedure has a problem that the graft liver would swing in 
the abdominal cavity and cause vascular torsion, and the circulation return will be 
affected. At present, the modified piggyback procedure used in most mature trans-
plant centers in China is below: inferior vena cava (VC) shaping: (1) recipient VC: 
according to the patient’s hepatic vein anatomy, the hepatic veins (left, middle and 
right) are split from the middle and trimmed into a continuous opening, and the 
front wall of inferior vena cava is also trimmed longitudinally, and all these together 
form an inverted triangular incision. (2) Donor VC: the posterior wall of the donor 
superior inferior vena cava was cut longitudinally with the two up angers of hepatic 
superior VC, also trimmed into an inverted triangular incision. Finally, these two 
inverted triangular incisions are anastomosed (Figure 4). The main purpose of this 
piggyback procedure is to enlarge the anastomosis of the outflow tract, avoid the 
anastomotic torsion, and reduce the incidence of postoperative outflow obstruction 
[39, 40].
4.3 Reduced-size liver transplantation and split liver transplantation
In our clinical work, the whole liver transplantation cannot meet the needs 
of liver transplantation in children and some small-weight adults, because these 
patients cannot accommodate the large-size liver in the abdominal cavity, which is 
why the reduced-size liver transplantation came into being [41]. Reduced-size liver 
transplantation actually includes reduced-size cadaveric liver transplantation, split 
liver transplantation, and partial living liver transplantation. By 2010, 86 trans-
plant centers in 30 provinces of Mainland China had undergone reduced-size liver 
transplantation. The donor liver for children with reduced-size liver transplantation 
Figure 4. 
The two “inverted triangular” incisions of donor and recipient’s inferior CV.
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is mainly the left liver. Split liver transplantation refers to the separation of an adult 
cadaveric donor liver into two transplanted livers with independent structures and 
functions by two-way technique, which is transplanted to two recipients. The con-
ventional method is to detach the liver along the Cantlie line and obtain the intact 
right and left hepatic livers, respectively [42, 43].
4.4 Auxiliary liver transplantation
Auxiliary liver transplantation refers to retaining the recipient’s liver or part of 
the liver, implanting the donor’s whole liver or part of the liver into the recipient, 
so that patients with liver failure can receive life support or compensate for the 
metabolism, detoxification, and other functions of the original liver deficiency [44]. 
It is divided into auxiliary ectopic liver transplantation and auxiliary orthotopic liver 
transplantation. The auxiliary liver transplantation has the following advantages: (1) 
patients with acute liver failure can pass the dangerous period, and (2) for congenital 
metabolic liver disease, implantation of a small amount of liver can meet the patient’s 
metabolic needs, (3) under surgical trauma, the recipient has no nonhepatic period, 
(4) the required liver volume is small, increase the donor liver source, and (5) for 
some patients within inability to tolerate the orthotopic whole liver transplantation, 
auxiliary liver transplantation should be performed first, and then the orthotopic 
liver transplantation should be considered after the recovery of the body function.
4.5 Living donor liver transplantation
Living donor liver transplantation has developed rapidly due to the severe lack 
of cadaver donor livers. In early years, the left half liver was used as the donor liver 
for living donor liver transplantation between adults, but for large-size recipients, 
the left half liver could not meet the demand of the recipient, so the right half liver 
was gradually used as the donor liver. The procedure of living donor liver transplan-
tation is basically the same as that of orthotopic liver transplantation, but there are 
many differences in the reconstruction of hepatic vein, portal vein, hepatic artery, 
and bile duct.
4.5.1 Hepatic vein reconstruction
In living donor liver transplantation, the right half liver as donor liver is divided 
into two types, including the hepatic middle vein and not including the hepatic 
middle vein. Whether the branches of the hepatic middle vein in hepatic segment V 
and VIII should be reconstructed in living donor liver transplantation of right half 
liver is controversial. Different liver transplantation centers have proposed different 
reconstruction criteria.
In the literature, B ultrasonography was used to assess congestion in the right 
half liver donation after temporary occlusion of the hepatic artery and the hepatic 
middle vein. Criteria for reconstruction of hepatic middle vein include: (1) after 
removing the area of the congestion, the remaining transplanted liver volume was 
less than 40% of recipient’s standard liver volume. (2) When hepatic artery and 
hepatic middle vein branches are blocked, the area of the donor liver congestion is 
more than half of the area of the right anterior lobe. (3) Noncongestive graft-to-
recipient weight ratio (ncGRWR) < 0.65%.
The diameter of the branches of the hepatic middle vein is also one of the criteria 
for reconstruction. The diameter of the branch of the hepatic middle vein in hepatic 
segments V and VIII was more than 7 mm, which was considered as the boundary of 
whether to reconstruct the branch of the hepatic middle vein. Kim et al. suggested 
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that when the hepatic middle vein branches of segments V and VIII were larger than 
5 mm in diameter, the hepatic middle vein branches needed to be reconstructed, and 
they tried to make the area of congestion less than 10% of the total graft volume [45].
In living liver transplantation without hepatic middle vein, the grafts used for 
reconstruction of hepatic middle vein include the recipient’s own great saphenous 
vein, superficial femoral vein, umbilical vein, portal vein, artificial blood vessel, 
iliac vein or iliac artery cryopreserved from allogeneic tissue, and also venous patch 
to reconstruct the branch of hepatic umbilical vein. Liver transplantation center 
of the first Hospital of Zhejiang University carried out a preliminary study on 131 
cases of living right donor liver transplantation without hepatic middle vein. The 
graft vessels were reconstructed by autologous portal vein, hepatic vein, great 
saphenous vein, or cryopreserved iliac artery to reconstruct the right hepatic vein 
branches V and VIII without hepatic middle vein [5].
4.5.2 Portal vein construction
After the portal veins of donor liver and recipient were in line with their caliber 
and length, they were performed with an end-to-end anastomosis. When the 
recipient of living donor liver transplantation has portal vein sclerosis or narrow 
problems, we anastomose the donor portal vein directly to the confluence of the 
recipient’s splenic vein and superior mesenteric vein. If the donor portal vein does 
not have enough length, portal vein transplantation can be performed.
4.5.3 Hepatic artery reconstruction
The reconstruction of hepatic artery in living donor liver transplantation 
is directly related to the success or failure of transplantation. The diameter of 
donor hepatic artery is only 2–3 mm. Arterial anastomosis under direct vision 
has been a difficult problem for many surgeons. Until the application of micro-
surgical vascular anastomosis under microscope, the incidence of hepatic artery 
thrombosis decreased from 25 to 0–3.8%. However, this technique is difficult to 
master and is influenced by arterial variations, donor-recipient caliber match-
ing, and recipient hemodynamics. Therefore, it is important to establish a stable 
microsurgical team and mature arterial anastomosis methods in various trans-
plantation centers.
4.5.4 Bile duct reconstruction
(1) Bile duct shaping: within 3 mm, the combination of adjacent hepatic duct 
opening can be considered.
(2) The principle of one-time suture insertion: in the so-called one-time suture 
process, the noninvasive suture needle from the recipient of the bile duct to the 
donor of the hepatic duct needle, must be completed at one time
(3) The basic bile duct end to end anastomosis technique: the posterior wall is 
continuously sutured, and the anterior wall is discontinuously sutured.
With the improvement of liver transplantation anesthesia, surgical techniques 
and perioperative management, the efficacy and survival rate of liver transplant 
patients have been significantly improved. With the accumulation of surgical 
experience, we need promotion of our surgical techniques. However, in view of 
the current situation of organ shortage in China, how to choose the most suitable 
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liver transplantation for different indications, preoperative status, and physiolog-
ical and anatomical features still needs to continuously explore and summarize 
the experience.
5. Complications after liver transplantation
5.1 Early complications after liver transplantation
5.1.1 Postliver transplant hemorrhage
Intraabdominal hemorrhage postliver transplantation is an early serious compli-
cation, and continues to be a prognostic factor for transplant success. Statistically, 
intraabdominal hemorrhage postliver transplantation occurs in 5–21% of recipients 
[46], while incidence rate of this complication in China is 5–15.3% [47, 48]. Reasons 
for intraabdominal bleeding after liver transplantation include coagulopathy, portal 
hypertension, massive transfusion of stored blood, primary graft non-function/
poor graft function, anastomotic leakage, as well as blood vessel damage by abdom-
inal infection. Coagulopathy is one of the most important risk factors for post-
operative early hemorrhage. Diffuse hemorrhage postreperfusion often occurs in 
recipients with coagulopathy, especially in those with poor liver function or lack of 
clotting factors. In addition, massive transfusion of stored blood leads to circulatory 
overload, abnormal coagulation and acid-base imbalance, resulted with aggravated 
hemorrhage symptoms. Surgical bleeding is related with operation of liver resec-
tion or graft harvesting. Furthermore, early hemorrhage may also occur as a result 
of blood vessel damage caused by anastomotic leakage or abdominal infection. 
Therefore, keeping normal coagulation function perioperatively, reducing bleeding 
and achieving effective hemostasis during operation, accurate anastomosis of blood 
vessels with vascular patency, as well as preventing and controlling infection, can 
contribute to prevention of this complication.
Therapeutically, correcting the clotting problem via giving blood products and 
coagulants is usually effective. However, patients with persistent hemodynamic 
instability, which indicates active hemorrhage, usually require emergency explor-
atory laparotomy for hemostasis.
5.1.2 Vascular complications
Vascular complications represent one of the most critical complications, and 
contribute to a major source of morbidity and mortality after liver transplanta-
tion. Vascular complications, including hepatic arterial complications, portal vein 
complications and vena cava complications, threaten outcomes for liver transplant 
recipients and graft survival. Among the vascular complications, hepatic arterial 
complications following liver transplantation are the most threatening conditions, 
including hepatic arterial thrombosis (HAT), hepatic artery stenosis, hepatic artery 
aneurysm, and hepatic artery rupture.
HAT is a life-threatening complication, as it interrupts blood supply of the 
allograft and induces early graft loss, long-term graft dysfunction, or recipient 
death. As the most common hepatic arterial complication, HAT occurs in 2–9% 
of adult transplants with a higher incidence in pediatric recipients [49, 50]. Risk 
factors for the development of HAT include technical imperfection with the anas-
tomosis, dissection of the hepatic arterial wall, celiac stenosis or compression by 
median arcuate ligament, aberrant arterial anatomy, complex back-table arterial 
reconstruction of the allograft, as well as high-resistance microvascular arterial 
outflow mediated by rejection or severe ischemic-reperfusion injury. According 
15
Liver Transplantation in China
DOI: http://dx.doi.org/10.5772/intechopen.81230
to the time of onset, HAT is divided into early HAT and late HAT. Early HAT, 
diagnosed less than 4 weeks after liver transplantation, shows various clinical 
manifestations, ranging from fulminant hepatic failure, recurrent biliary sepsis, 
or delayed biliary leaks to an asymptomatic presentation with abnormal liver 
function. Compared with early HAT, clinical presentation of late HAT is relatively 
reduced, varied from increased serum transaminase level with or without cho-
lestasis to liver abscess and biliary complications such as ischemic biliary lesions, 
cholangitis, bile duct stenosis, or necrosis. Early diagnosis with emergent surgical 
intervention is lifesaving and contributes to graft survival. Diagnosis of HAT 
depends on imaging examinations, while surgical exploration can confirm diagno-
sis. In clinical setting, arteriography is recognized as gold standard for diagnosis 
of HAT following liver transplantation. Patients with early HAT and fulminant 
hepatic failure require resuscitation, broad-spectrum antibiotics, artificial liver, 
and expeditious retransplantation.
Hepatic artery stenosis is one of the most common complications postliver 
transplantation, with incidence rate ranging from 4 to 11% [51, 52]. This stenosis 
most commonly occurs in anastomosis site or the kinking of reconstructed artery. 
Factors associated with hepatic artery stenosis include surgical injury, vasospasm, 
anastomotic stenosis, high-resistance hepatic artery blood flow mediated by rejec-
tion, and cold preservation injury. Clinical presentation varies from abnormal liver 
function to severe biliary complications. If unrecognized and managed appropri-
ately, hepatic artery stenosis will lead to complete occlusion of hepatic artery or 
thrombosis, resulting in ischemic infarction and graft failure. Angiography is the 
gold standard for diagnosis of hepatic artery stenosis. Therapeutically, interven-
tional vascular procedures are current major treatment.
Hepatic artery aneurysm and hepatic artery rapture are rare complications after 
liver transplantation, with an incidence of 0.3–1% [53, 54]. However, these compli-
cations can also threaten patients and grafts.
5.1.3 Biliary complications
The incidence of biliary complications has decreased dramatically because of 
advances in liver transplantation; however, biliary complication remains the most 
frequent complications postliver transplantation, with an incidence of 26.92–53.8% 
[55, 56]. Biliary complication is no longer a major cause of mortality in experienced 
liver transplantation center, as these complications can be recognized early and 
revive timely effective management. But biliary complication exhibits impact on 
patients’ life quality, and sometimes it enables development of graft dysfunction. 
Therefore, biliary complication remains a challenging complication.
Biliary complications include bile leakage, anastomosis stenosis, bile duct isch-
emic injury, gall-stone formation, and sphincter dysfunction. Bile leakage, either 
anastomosis leakage or bile leakage after removal of T-tubes, usually occurs early 
postliver transplantation. Anastomosis stenosis is frequent. Endoscopic therapy 
and interventional radiology treatment are proven to be effective in treatment of 
anastomosis stenosis. Bile duct ischemic injury is a major cause of bile leakage, bile 
duct stenosis, or dilatation, followed by biliary sludge and cholelithiasis. Gall-
stone formation is mainly found in donor liver bile duct, but can also be observed 
in recipient’s bile duct. Sphincter dysfunction is a complication hard to diagnose. 
Among the biliary complications after liver transplantation, bile duct ischemic 
injury is the most dangerous disease with high mortality. Patients with serious bile 
duct ischemic injury finally will need retransplantation. Surgical imperfection and 
bile duct ischemia are the major causes of biliary complication. Accurate bile duct 
anastomosis without distortion of the bile duct, proper use of T-tube, avoiding 
excessive trimming of vessels, and protecting blood supply of bile duct will promote 
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reconstruction of bile duct and reduce bile duct complications after liver transplan-
tation. Immunosuppressants can also contribute to this complication, such as CsA 
promotes cholestasis and gall-stone formation.
Clinical presentation of biliary complication varies. Patients with bile leakage 
usually have mild or moderate abdominal pain, with bile drained out from drain-
age tube or biliary spillage from umbilical incision. Symptoms of serious bile duct 
stenosis include jaundice in a short time. Early symptoms of patients with bile duct 
ischemic injury are atypical, sometimes similar to bile leakage, but late symptoms of 
bile duct ischemic injury like bile duct stenosis. Gallstones may occur secondary to 
bile duct stenosis, and patients with serious bile duct obstruction usually will have 
abdominal pain and jaundice.
With advances in imaging and endoscopic therapy, biliary complications can 
be diagnosed early and interventional treatment has become the first choice for 
patients with biliary complications after liver transplantation.
5.2 Late complications
With advances in transplant technique, liver transplant recipients achieve a 
longer life longevity and prolonged graft survival. Meanwhile, late complications 
postliver transplantation gradually become critical factors of their life quality and 
graft long-term survival.
5.2.1 Metabolic complications
5.2.1.1 De novo diabetes
De novo diabetes after liver transplantation is critical for outcomes of patients, 
correlated with a higher incidence of infection or cardiovascular diseases postliver 
transplantation. And it contributes to graft dysfunction and lower recipients’ survival. 
According to definition of diabetes mellitus from WHO and ADA, de novo diabetes 
occurs in 9–63.3% patients with liver transplantation [57, 58]. Immunosuppressants, 
such as corticosteroid use and calcineurin inhibition, are risk factors for de novo 
diabetes. Appropriate use of immunosuppressant, including dose and duration, is of 
significance for preventing de novo diabetes postliver transplantation.
5.2.1.2 Hyperlipidemia
Hyperlipidemia is a common complication is solid organ transplantation, which 
can significantly promote incidence of chronic cardiac diseases in organ recipients. 
The incidence rate of hyperlipidemia in liver recipients is 45–66% [48, 58, 59]. 
Elevations of serum cholesterol and triglyceride are common consequences of use 
of immunosuppressants. Particularly, steroids and cyclosporine are closely associ-
ated with higher levels of cholesterols and triglyceride, while sirolimus exerts a 
stronger impact on triglyceride levels. Life style modifications with diet, exercise, 
and weight loss are preferred treatments. Besides, HMG-CoA reductase inhibition 
requires caution, as it may cause hepatotoxicity.
5.2.1.3 Hyperuricemia
Hyperuricemia is common in patients with liver transplantation, which usually 
occurs in 17–60 months postliver transplantation. The incidence rate of hyperuri-
cemia in patients received liver transplantation is 14–47% [60, 61]. Mechanically, 
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long-term use of calcineurin inhibitors leads to kidney injury and impairs the 
capability to clear uric acid, resulted with elevated uric acid levels or gout.
5.2.2 Biliary complications
Although huge advances have been made in liver transplantation, including 
biliary reconstruction, organ preservation and perioperative management, the inci-
dence of biliary complications after liver transplantation remains high, up to 53.8% 
[56]. Biliary complications include biliary stenosis, bile leakage, ampulla dysfunc-
tion, biliary silt, and gallstone formation. However, biliary stenosis and gallstone 
formation are major late complications. As biliary reconstruction is recognized as 
Achilles’ heel of liver transplantation, biliary reconstruction technique is strongly 
correlated with biliary complications. Besides, poor blood supply of hepatic 
artery and injury caused by donor liver harvest, cold preservation, or reperfusion. 
Furthermore, infection is also an important cause of biliary complication.
5.2.3 Recurrent disease
Recurrent liver diseases after liver transplantation is a common late complica-
tion, including hepatitis B, nonalcoholic fatty liver disease, autoimmune hepatitis, 
primary biliary cirrhosis as well as primary sclerosing cholangitis; however, the 
risk and timing of recurrent liver diseases are variable. Of note, recurrent hepatitis 
B virus (HBV) infection can be prevented in compliant patients with hepatitis B 
immunoglobulin and anti-HBV drugs. However, poor therapy compliance with 
irregular immunosuppressants application allows recurrence of HBV infection. In 
addition, recurrent autoimmune hepatitis or primary biliary cirrhosis rarely cause 
graft dysfunction or require retransplantation, though there are no proven effective 
therapies for the treatment of these late complications.
6. Indications for liver transplantation
Liver transplantation is an important option to treat the end-stage liver 
diseases and aims to prolong the life survival and to improve the quality of life 
for the patients. In principle, any acute or chronic liver disease, which has no 
other effective treatment or would cause the death of the patient in a short time, 
should be the indication to liver transplantation. With the increasing advance 
of liver transplantation, it can also be performed to improve the quality of life, 
although the primary liver disease might not be cured. The detail indications 
include the following:
(a) Acute liver failure: infections, drug- or toxin-induced liver injury, circulatory 
disturbance, etc.
(b) Liver cirrhosis: hepatitis cirrhosis, alcoholic cirrhosis, cholestatic cirrhosis, etc.
(c) Liver neoplasms: hepatocellular carcinoma, cholangiocarcinoma, etc.
(d) Metabolic disorders: Wilson disease, alpha-1 antitrypsin deficiency, hereditary 
tyrosinemia, glycogen storage disease, etc.
(e) Others: autoimmune hepatitis, polycystic liver, trauma, etc.
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The contraindications, although decreasing with the development of liver 
transplantation, generally include the following:
(a) Malignancy outside of the liver and cannot be radical cured
(b) Uncontrolled sepsis
(c) Excessive drinking or drug abuse
(d) Severe cardiopulmonary, encephalic or renal complications
(e) Acquired immunodeficiency syndrome (AIDS)
(f) Persistent nonadherence with medical care
(g) Uncontrolled psychological or mental diseases
According to the China Liver Transplant Registry (CLTR), the most common 
disease leading to liver transplantation from DCD was liver neoplasms (42.98%), 
following by liver cirrhosis (41.05%) and acute liver failure (9.07%) from 2010 to 
2017. The model for end-stage liver disease (MELD) or MELDNa score is applied to 
evaluate the status of the patients and to determine the priority of recipients and 
the allocation of organs by the CLTR.
6.1 Liver transplantation for hepatocellular carcinoma
It was estimated that more than 300,000 patients died of hepatocellular car-
cinoma (HCC) in China, which accounted for half of the total deaths all over the 
world [62]. The main reason was the high rate of hepatitis B virus (HBV) infection. 
In recent years, liver transplantation has become an effective treatment to HCC, 
in which the en bloc resection of the tumor can be achieved and the cirrhotic liver 
can be replaced. According to the CLTR, HCC was one of the most common causes 
leading to liver transplantation from DCD in China, with the 1- and 5-year survival 
rate of 82.77 and 59.18%, respectively (CLTR, 2010–2017). With the large number of 
practices, the Chinese experience was summarized.
6.1.1 Indications
The Milan criteria (a single lesion ≤5 cm, or up to three lesions, all ≤5 cm; no 
macrovascular invasion; no regional nodal or extrahepatic distant metastases) are 
the benchmark for selection of appropriate candidates for liver transplantation due 
to HCC. However, few patients in clinical practice could fully meet these strict crite-
ria so that they might lose the opportunity of transplantation. Even expanded to the 
University of California at San Francisco (UCSF) criteria or Pittsburgh criteria, the 
number of candidates meeting the criteria is still limited in China. During the past 
decades, many Chinese scholars tried to expand the boundary of the indication, and 
concluded the criteria suitable for the Chinese situation.
(1) Hangzhou Criteria.
The Hangzhou Criteria were proposed by Prof. Shu-Sen Zheng, etc. in 2008 [63]. 
The criteria contained one of the two following items: (a) total tumor diam-
eter ≤8 cm; (b) total tumor diameter > 8 cm, with histopathologic grade I or II 
and preoperative alpha fetoprotein (AFP) level ≤ 400 ng/mL, simultaneously. 
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Obviously, Hangzhou Criteria significantly expanded the candidate pool, and 
the reported 5-year survival rate was comparable to that of patients fulfilling 
Milan criteria (72.3 versus 78.3%, P > 0.05). More importantly, these criteria not 
only considered the tumor size, but also included the histopathologic grading 
and serum AFP level, which better reflected the biological characteristics of the 
tumor and predicted the prognosis. In Chinese guidelines of liver transplanta-
tion to HCC 2014, Hangzhou criteria were recommended [62].
(2) Shanghai Fudan Criteria.
Compared to Milan criteria, Shanghai Fudan Criteria expanded the indica-
tions on the tumor size: single lesion ≤9 cm in diameter, or no more than three 
lesions, the largest ≤5 cm, with a total tumor diameter ≤ 9 cm. There was no 
significant difference in 1, 2, 3-year survival rates and recurrence-free survival 
rates between Milan criteria and Shanghai Fudan Criteria [64].
6.1.2 Downgrade treatment of HCC before transplantation
The early diagnosis of HCC in China is limited so that a large number of patients 
are diagnosed with advanced HCC. Even if the expanded criteria were applied, many 
patients still lose the opportunity of transplantation. For patients without macrovas-
cular invasion or extrahepatic distant metastases but beyond the current indications, 
downgrade treatments are proved effective to make part of the patients available to 
liver transplantation [65, 66]. The main downgrade treatments include transcatheter 
hepatic arterial chemoembolization (TACE), and local ablation therapy (radio-
frequency ablation, microwave ablation, cryoablation and percutaneous ethanol 
injection) [62]. The combination of multiple therapies may achieve better efficacy.
6.1.3 Antivirus treatment
It was reported that over 90% of the HCC patients in China were related to the 
HBV infection. The high HBV load would increase the risk of tumor recurrence 
so that antivirus treatment is recommended pre-, intra- and posttransplantation. 
Before transplantation, the candidate should receive the nucleotide analogues 
(NAs) like entecavir and tenofovir as soon as possible to reduce the HBV load. 
During the nonhepatic phase in operation, the hepatitis B immunoglobulin (HBIG) 
is administered to block the viral transmission. After transplantation, the combina-
tion of NAs and low-dose of HBIG is recommended. HBV vaccines are given to 
some recipients posttransplantation, but the effects are still controversial.
6.1.4 Immunosuppression and prevention of tumor recurrence
The triple immunosuppressive regimens (CNI + MMF + corticosteroids) 
still consist the footstone of immunosuppression for HCC liver transplantation. 
Although CNI is reported as an independent risk factor for tumor recurrence, 
complete drug withdraw is not recommended. The mammalian target of rapamycin 
(mTOR) inhibitor like sirolimus or everolimus, which has the potential for the 
inhibition of tumor growth, has been applied with the induction of IL-2 receptor 
antagonist (IL-2RA) in some centers in China. What is advocated currently is the 
individualized regimen based on the individual’s immune status. The main regi-
mens used in clinic include the followings: (1) CNI + MMF + corticosteroids, (2) 
IL-2RA + sirolimus/everolimus + MMF + corticosteroids, and (3) IL-2RA + siroli-
mus/everolimus + MMF [62].
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The recurrence of HCC is the main hinder for the long-term survival of these 
patients. Reportedly, the recurrence rate reached 20.0–57.8%; thus, it is critical 
to prevent the recurrence posttransplantation [67, 68]. The effective treatments 
include 131I-labeled metuximab, sorafenib, and chemotherapy. The choice depends 
on the morphological features, neoplasm staging, gene typing, histological grade, 
and biological characteristics of the tumor.
6.2 Liver transplantation for viral hepatitis
In China, viral hepatitis is mostly caused by HBV infection, and the prevalence 
of HCV is low. National Hepatitis Serum Epidemiology Survey [69, 70] showed that 
the HBsAg carrier rate in China’s general population aged 1–59 years was 7.18%, while 
the anti-HCV prevalence rate was about 0.43% [71]. Based on this, there are about 
93 million people with chronic HBV infection [72], and for HCV infection, this data 
are 5.6–10 million [73]. Patients with end-stage chronic hepatitis B have become the 
main population of liver transplant recipients in China. According to the China Liver 
Transplant Registry (CLTR) 2015 statistics, patients with viral hepatitis-associated liver 
disease accounted for 74.79%, and hepatitis B virus (HBV)-related liver disease patients 
accounted for 71.25%. Therefore, the following mainly describes the problems faced by 
liver transplantation in the treatment of hepatitis B virus-associated liver disease.
6.2.1 Indications
Similar to other indications for liver transplantation in chronic liver disease, liver 
transplantation should be considered when the following conditions occur:
(a) Patients undergoing systemic medical treatment, but the expected survival time 
is shorter than 2 years
(b) Recurrent esophageal varices bleeding after endoscopic treatment
(c) Refractory ascites
(d) Chronic hepatic encephalopathy
(e) Occasional bacterial peritonitis
(f) Liver cancer that occurs on the basis of hepatitis B
6.2.2 Prevention of hepatitis B virus recurrence after transplantation
The choice of patients with viral liver disease as recipients of liver transplanta-
tion was once controversial. The main reason is the high recurrence rate of viral 
hepatitis after transplantation. Although the liver transplantation completely 
removes the diseased liver, the extrahepatic tissue and blood are inevitably left with 
a small amount of residual virus, which causes the reinfection of HBV in liver. It 
was reported that the recurrence rate of hepatitis B after liver transplantation for 
hepatitis B-related liver disease is up to 70–80% in China [74, 75].
The recurrence of hepatitis B is affected by a variety of factors. The use of 
immunosuppressive agents, preoperative HBV at high replication levels, and 
without other viral coinfections will increase the rate of postoperative hepatitis B 
recurrence. In addition, HBV genotypes can also affect the recurrence of hepatitis B 
after transplantation [76]. Among them, the gene D has the highest recurrence rate.
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The study found that patients with HBV reactivation after liver transplantation 
have more serious hepatocyte damage and faster fibrosis progression [77]. In the 
short term, it can rapidly develop into fibrous cholestatic hepatitis, cirrhosis, or 
acute liver failure, resulting in the death of the recipient. Therefore, prevention and 
treatment of recurrent hepatitis is particularly important.
The practice guideline on prophylaxis and treatment of hepatitis B for liver trans-
plantation in China recommended that HBV DNA should not be detected as much 
as possible or the HBV DNA level should be minimized before transplantation [78]. 
Therefore, antiviral drugs such as high-resistance gene barrier NAs (ETV or TDF) 
should be routinely applied before transplantation. In the liver transplantation, the 
fully use of HBIG to neutralize HBsAg is a key measure to prevent HBV infected the 
new liver. After transplantation, the “NAs combined with low-dose HBIG” regimen 
should be used, which could significantly reduce the risk of hepatitis B recurrence.
HBsAg, HBV DNA, and anti-HBs titers should be frequently detected within 
6 months after HBV-related liver transplantation to monitor HBV replication and 
reinfection, and to determine the dose and frequency of HBIG use. During follow-
up, the recipient’s anti-HBV titer, which suddenly decreased or wore off, often 
indicates the recurrence of HBV, so that the therapeutic regimen should be adjusted.
6.2.3 Treatment of HBV reinfection/emerging infection after liver transplantation
HBV reinfection/emerging infection after liver transplantation progresses 
relatively rapidly, which can lead to liver failure and even death of patients. It is 
necessary to carry out targeted evaluation and treatment as soon as possible, aiming 
to rapidly inhibit HBV replication in the short term and to avoid serious liver injury. 
After the HBV reinfection/emerging infection, HBIG should be discontinued and 
treated with high-resistance gene barrier NAs, and HBV-resistant mutant genes and 
regulatory drugs should be tested. Intensive monitoring of HBV DNA levels and liver 
injury indicators should be performed. When the liver injury indicators are abnor-
mal, the pathological examination of the liver tissue should be considered, and the 
degree of liver injury and disease progression comprehensively determines whether 
the liver transplantation should be evaluated again.
In the selection of NAs drugs, in addition to the resistance mutation fac-
tors, some scholars believe that HBV genotype should also be a reference factor. 
According to the difference of HBV gene sequence, it can be divided into 10 
genotypes of A-J [79]. In China, HBV infection is mainly B/C type [70]. Numerous 
studies have shown that the antiviral efficacy of NAs is affected by the HBV geno-
type. Among them, Chinese literature reports that the antiviral efficacy of NAs is 
significantly different between HBV gene type B and type C [80–83]. It is summa-
rized in the following table.
At present, the mechanism by which different genotypes of HBV react differ-
ently to antiviral drugs is still unclear. Moreover, some scholars have found that the 
genotype does not affect the antiviral efficacy of the drug, and may be related to the 
different genotype detection methods used by different researchers and the sample 
size. In conclusion, there is no consensus on the effect of HBV genotype on the 
antiviral efficacy of NAs. The specific mechanism and its correlation require further 
clinical observation and basic experimental research to guide clinical antiviral drug 
treatment and efficacy judgment (Table 2).
6.3 Liver transplantation for alcoholic liver disease
Alcoholic liver disease is caused by long-term heavy drinking. In the early stage, 
it usually manifests as fatty liver, which in turn can develop into alcoholic hepatitis, 
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liver fibrosis, and cirrhosis. In severe alcohol abuse, extensive hepatocyte necrosis 
can be induced and even cause liver failure.
According to the 2014 World Health Organization report, the per capita alcohol 
consumption of Chinese people over the age of 15 is about 6.7 L/year, and 4.8% of the 
population has alcohol use disorders, including 9.1 and 0.2% for men and women, 
respectively. Overall, the proportion of Chinese drinkers and the prevalence of alco-
hol-related liver diseases are on the rise. According to epidemiological survey data of 
alcohol related liver disease in some provinces, the prevalence of alcohol-related liver 
disease is 0.50–8.55% [84–86]. From 2000 to 2004, the proportion of alcohol-related 
liver disease in hospitalized patients with liver disease had increased from 2.4 to 4.3% 
[87]. The proportion of patients with alcoholic cirrhosis in all patients with cirrhosis 
increased from 10.8% in 1999 to 24.0% in 2003 [88, 89]. Alcohol-related liver disease 
has become one of the most important chronic liver disease in China [90].
6.3.1 Indications
It is generally believed that liver transplantation should be considered when 
patients with alcoholic liver disease meet the following conditions:
(a) Fail to respond to medications.
(b) Liver lesions are severe or end-stage liver disease manifests.
(c) Suspected small liver cancer is present (single nodule <5 cm, 1–3 nodules <3 cm).
(d) No serious alcohol damage in other organs.
(e) After comprehensive factor evaluation, it is determined that there is a lower post-
operative recovery of alcohol abuse.
6.3.2 Assess the risk of relapse after transplantation
Studies have shown that the 3-year survival rate of alcoholic patients after 
liver transplantation is significantly lower than that of nonalcoholic groups [91]. 
Therefore, in patients with alcoholic liver disease, whether or not successful alcohol 
withdrawal after liver transplantation becomes the key. Predictors of longer postop-
erative alcohol withdrawal include: (1) the patient recognizes the severity of alcohol-
ism. (2) The patient has a stable residence. (3) The patient has a stable occupation. 
(4) The patient has at least one closely related patient to provide spiritual support.
The following factors represent a higher risk of restocking. (1) The patient has had 
psychological or mental disorders. (2) The patient has unstable personality character-
istics. (3) The patient has repeatedly failed to stop drinking. (4) The patient has the 
NA species The difference of the curative effect
ETV/entecavir B > C
LAM/lamivudine B > C
ADV/adefovir dipivoxil No significant difference
TDF/tenofovir disoproxil fumarate No significant difference
LdT/telbivudine B > C
Table 2. 
NAs make a different curative effect in different HBV genotypes.
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habit of drug abuse. (5) The patient’s social relationship is isolated. In practice, effec-
tive preventive education measures can significantly reduce the patient’s redrinking 
after surgery. At present, the Chinese guidelines are feasible for liver transplanta-
tion in patients with alcoholic liver disease who require alcohol withdrawal for 
3–6 months before liver transplantation and no serious alcohol damage in liver.
6.4 Liver transplantation for metabolic diseases
Liver is an important metabolic organ of the human body. Therefore, congeni-
tal metabolic diseases caused by defects in certain key metabolic steps are often 
associated with the liver damage. Some genetic metabolic diseases are manifested 
in liver disease in infants or children. As the disease progresses, nerves, kidneys, 
heart, bones, vision, hearing, and skin mucosa are damaged. Liver diseases can 
also aggravated, leading to cirrhosis and liver failure. These diseases are collectively 
referred to as hereditary metabolic liver disease.
There are many kinds of genetic metabolic diseases, and the etiology is compli-
cated, 50–60% in childhood. At present, there are more than 600 kinds of heredi-
tary metabolic liver diseases, including carbohydrate metabolism disease, amino 
acid metabolism disease, fatty acid metabolism disease, organic acid metabolism 
disease, mitochondrial liver disease, lysosomal disease, peroxisome disease, and 
metal. There are nine categories of metabolic disorders and 1-antitrypsin deficiency.
Liver disease progresses to advanced cirrhosis or liver failure and requires liver 
transplantation. According to CLTR, 0.69% of the liver transplantation from DCD is 
caused by hereditary metabolic liver diseases. In living donor liver transplantation, 
the rate is 4.13%.
The clinical manifestations of genetic metabolic diseases are diverse, and the 
symptoms are often not limited to the liver. Since some hereditary metabolic liver 
diseases often involve multiple organ systems, liver transplantation cannot solve the 
lesions outside the liver, leading to a poor prognosis. There are certain limitations in 
liver transplantation in this respect. For example, the effect of simple liver trans-
plantation on patients with progressive familial intrahepatic cholestasis type 1 is not 
ideal. For these diseases, it is often necessary to cooperate with other treatments. 
For example, for hyperglycinemia, liver transplantation can only improve the 
clinical symptoms, and patients can continue to excrete succinylacetone in the urine 
after surgery. Therefore, some cases need to be combined with liver and kidney 
transplantation to correct metabolic abnormalities.
7. Immunosuppressants for liver transplantation
With the rapid development of liver transplantation technology, immunosup-
pressive drugs and drug regimens have emerged in endlessly, playing an increasingly 
important role. Looking back, medical pioneers had to use crude technical means such 
as whole-body x irradiation. Until the advent of cyclosporine, liver transplantation 
has gradually become the main stream of treatment for liver failure. Today, drugs like 
azathioprine have almost withdrawn from the stage of history. More and more novel 
immunosuppressants and different strategies are coming into view. Understanding 
each agent’s potency and deficiencies is an essential part of clinical practice. No 
immunosuppressant is universally applicable yet. Patients with renal impairment, 
malignancy, or autoimmune diseases may need specific agent or regimen. Therefore, 
individualized treatment is essential. Here, some commonly used immunosuppres-
sants will be briefly introduced and discussed. Emphasis will be placed on the clinical 
application, rather than the mechanism of agents (Table 3 and Figure 5).
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7.1 Calcineurin inhibitors
Cyclosporine and tacrolimus are two well-known calcineurin inhibitors (CNIs). 
Both of them are discovered from the soil fungus and are mechanistically similar. 
They can suppress the immune system by inhibiting interleukin 2 (IL2) gene 
transcription. Cyclosporine’s effect is mediated by cyclosporine’s association with 
cyclophilin, while the tacrolimus’s effect is mediated by a specific interaction 
with FK-binding protein-12 (FKBP12), both of which can result in inhibition of 
the calcium/calmodulin-dependent phosphatase complex calcineurin, hence the 
designation “calcineurin inhibitor” (or CNI). An important distinction is that the 
immunosuppressive potency of tacrolimus is estimated to be 100-fold greater on 
a molar level. Due to their powerful capacity in reducing acute rejection, the CNIs 
have been playing an important role in immunosuppression regimens postliver 
transplantation. As it should be noted that most recent trials use tacrolimus 
monotherapy or tacrolimus-based therapy as the control group, suggesting that 
tacrolimus is considered the standard against, which other immunosuppressants 
are compared.
Despite the potency of CNIs, some serious problems remain. The CNIs may have 
close relationship with renal toxicity, HCV reinfection, hepatocellular carcinoma 
recurrence, and some other negative effects [92–94]. So how to use CNIs properly in 
liver transplantation is a conundrum. At present, to perform therapeutic drug monitor-
ing to reduce the chance of overdosing is necessary, but not enough. The only reason-
able step when facing those complicated cases is to minimize or eliminate CNI use.
7.2 Antimetabolites
As for antimetabolites, what is popular now is mycophenolate mofetil (MMF; 
Hoffmann La Roche, Basel, Switzerland), which is a prodrug of mycophenolic acid 
(MPA). It takes effect through inhibiting inosine-59-monophosphate dehydroge-
nase (IMPDH), an important enzyme for de novo synthesis of guanosine nucleo-
tides. Thanks to Sollinger, MMF was brought to the clinic in the early 1990s and 
used as an immunosuppressant from then on.
Another prodrug of MPA being used clinically is referred to as enteric-coated 
mycophenolate sodium (ECMPS; Novartis, Basel, Switzerland). Different from 
MMF, EC-MPS is not rapidly absorbed in the stomach; it is a delayed-release 
drug formulation that allows release of MPA in the small intestine via a pH-
dependent dissolution. The research and development of EC-MPS was trying to 
solve the well-known gastrointestinal side effects of MMF. However, things are 
not as smooth as imagined. Studies have not demonstrated fewer side effects with 
EC-MPS [95].
Due to the renal toxicity of CNI, MMF and EC-MPS are playing an increasing 
potential role in liver transplantation as they basically have no nephrotoxicity. 
Several studies have now shown that MMF and EC-MPS are superior to CNIs in 
terms of renal function, at the cost of a higher rejection rate [96]. For now, compro-
mise is inevitable in such situation. Regimens like “MMF/EC-MPS +low dose CNIs” 
are acceptable [97].
As mentioned above, MMF and EC-MPS are not without side effects. Both 
gastrointestinal disorders and hematological suppression are concerns that cannot 
be ignored.
By the way, azathioprine (AZA) is another antimetabolite that has left an 
important part in the history of liver transplantation. Though its role for preventing 
rejection has been almost completely replaced by MMF/EC-MPS, some researches 


























Immunosuppressants Action Merits Demerits
T cell activation inhibitors Cyclosporine Inhibits calcineurin via cyclophilin, blocking IL2 transcription • Reliable antirejection effect




Tacrolimus Inhibits calcineurin via FKBP12, blocking IL2 transcription
T cell proliferation 
inhibitors
MPA prodrugs IMPDH inhibitor: enzyme required for de novo synthesis of guanosine  
nucleotides, required for
lymphocyte proliferation
• Low renal toxicity • Acute rejection




mTOR blockade prevents IL2-induced T cell proliferation • Less renal toxicity • Wound healing↓, 
mouth ulcers, 
hyperlipidemia
Azathioprine Inhibits purine synthesis, thereby blocking immune cell proliferation • Cheap
• Possible anti-HCV effects




Comparison of common immunosuppressive agents.
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7.3 mTOR inhibitors
Mammalian target of rapamycin (mTOR) inhibitors include sirolimus (rapamy-
cin; Wyeth) and everolimus (a rapamycin derivative; Novartis). Rapamycin was 
first discovered in soil from Easter Island (Rapa Nui). Researchers were trying to 
find its fungi inhibiting ability while accidentally found its immunosuppressive 
effect. Rapamycin can bind to FKBP12 and form FKBP12 immunosuppressive 
complex, which can bind to and inhibit the activity of mTOR, thus inhibiting the 
development of G1 to S phase in cell cycle. Unlike the CNI effects, rapamycin allows 
T cell activation, but prevents cells from proliferating in response to IL2.
mTOR inhibitors have been approved for use in renal and heart transplantation 
in combination with CNIs, but not in liver transplantation so far. The use of mTOR 
inhibitors may cause several adverse reactions:
(a) It may be related to the development of early posttransplant hepatic artery 
thrombosis, though not confirmed [100, 101].
(b) It may elevate blood lipids (cholesterol).
(c) It may cause wound-healing delays, leg edema and mouth ulcers.
(d) However, this is not to say that mTOR inhibitors have no advantage in liver 
transplantation.
(e) It may reduce early renal dysfunction compared to CNIs.
(f) It may promote liver allograft tolerance compared to CNIs [102, 103].
(g) It has antitumor effects compared to CNIs [104, 105].
(h) It may have antifibrosis effect [106].
All in all, although mTOR inhibitors are not approved for use in liver transplan-
tation yet, they have good reasons for further investigation.
7.4 Steroids
No doubt, steroids have made great contributions through the development of 
liver transplantation. For many years, they have been fighting against rejection. 
Figure 5. 
The mechanism of common immunosuppressive agents.
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While as always the case, their utilization today is controversial. On one hand, 
corticosteroids have a wide range of immunosuppressive properties:
(a) Inhibit arachidonic acid metabolism
(b) Affect antigen presentation by dendritic cells
(c) Inhibit IL1-dependent lymphocyte activation by decreasing IL1 transcription
Their broad spectrum of effects provides excellent anti-inflammatory activity 
that often reverses ongoing allograft rejection.
Of course, their side effects are also well known such as diabetes, hypertension, 
osteoporosis, obesity, etc. Besides, researches also suggested that high-dose steroids 
may exacerbate HCV infection and fibrosis, especially when used as pulse therapy 
for antirejection treatment [107]. Thus, how to use steroids in a proper way is still 
a pending problem. A variety of steroid-free/minimization immunosuppressive 
protocols in liver transplantation are under evaluation [108].
7.5 Other promising immunosuppressants or therapy
Due to space limitations, we did not talk about biologic agents like ATG and 
basiliximab, and will not discuss those promising agents such as belatacept, alemtu-
zumab and efalizumab, or cellular-based therapy, which may be widely used in liver 
transplantation in the future. For details, readers can refer to [109].
7.6 Common solutions and suggestions
Tacrolimus-based therapy: “Tac + MMF + steroids” or “Tac + steroids.”
Day 0 (the day of the operation): methylprednisolone 500 mg, intravenous, 
intraoperative; no Tac.
Postoperation: Tac 0.05 mg/(kg*d), twice, later adjust the dose according to 
blood concentration; methylprednisolone, gradually decrease the dosage, and on 
day 7 changed to prednisone 20 mg, oral administration; MMF 1.5–2 mg/d, twice.
About 24–48 hours after Tac administration, blood concentration should be 
tested, and together with other clinical results adjust the Tac dosage.
Steroids withdrawal strategy: day 0, methylprednisolone 500 mg, intravenous, 
intraoperative; day 1, 240 mg; then decrease 40 mg every day; day 7, change to 
prednisone 20 mg, oral administration. 1 month postoperation, start to decrease 
prednisone dosage, decrease 2.5 mg every 2 weeks. For hepatic cancer and hepa-
titis C recipients, the process of reducing the dosage should be fast. While for the 
primary biliary cirrhosis and combined liver kidney transplantation recipients, the 
process should be slower. In addition, gastric protective drugs should be used when 
steroids are used.
For better-individualized medication, we have to understand the merits and 
demerits of each immunosuppressant available for liver transplantation, along 
with each patient’s condition. On this individualized basis, our ultimate goal is to 
minimize or even eliminate long-term pharmacological immunosuppression in liver 
transplantation recipients. Though difficult, it is worth the effort.
8. Postoperative follow-up of liver transplantation
Nowadays, with the improvement of the surgical techniques of liver transplanta-
tion and the update of immunosuppressive agents, liver transplantation in china 
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is getting more and more mature, which has already been in line with the interna-
tional standards, approximately 95% of patients can safely get through the periop-
erative period and discharge from hospital [110, 111]. With the increasing of cases 
of liver transplantation and the prolongation of life span, the patients’ long-term 
treatment and follow-up work have been paid more and more attention by experts 
and related scholars.
The follow-up of liver transplantation is a long and complex work, which is 
mainly characterized by large data volume, individual differences, and long follow-
up period (generally, lifelong follow-up). An efficient and reasonable follow-up 
system can not only improve the efficiency of the transplant center, but can also 
increase the rate of survival of patients. With the gradual standardization of liver 
transplantation, an ideal postoperative follow-up system has become an important 
indicator of a mature liver transplantation center.
8.1 Meaning of regular follow-up
Through regular follow-up, the clinicians can dynamically observe the rehabili-
tation, mental state and medication situation of liver transplant recipients, and give 
necessary guidance and health education. In the follow-up, the clinicians can detect 
and deal with the complications after liver transplantation in time, improve the 
quality of life, prolong the survival period after the operation. Because the inci-
dence of tumor after transplantation is higher than that of the general population, 
especially liver transplantation of HCC patients may lead to tumor recurrence and 
metastasis, follow-up regularly can promptly detect the tumor and give appropriate 
treatment. Moreover, follow-up is the need of medical model transformation, which 
makes up for the shortage of medical resources, is a tracking service and also an 
active service. In today’s China acute contradiction between doctors and patients, 
follow-up is a very good way of communication, which can make the relationship 
between doctors and patients more harmonious and understand each other more. 
Meanwhile, collection of information of the regular follow-up can accumulate valu-
able experience for clinical and scientific research [112].
8.2 Development and method of follow-up in China
Liver transplantation centers in China are in different stages of development, 
and each center should choose a suitable follow-up method according to its out-
patient follow-up volume and staffing. With the increase of liver transplantation 
cases, our center has established the database for recipients’ management and 
follow-up since 2002, which is constantly updated and improved. In the early stage 
of liver transplantation, many centers in China lack a sound follow-up system, 
which is passive and sporadic. In 2008, China Liver Transplantation Registry 
(CLTR) came into use, the first liver transplantation scientific registration system 
in China, which is an intelligent data collection and management system in line 
with the characteristics of organ transplantation in China [48]. It sets up a good 
platform for clinical evidence-based medicine and the scientific research and 
provides patients with high-quality medical service at the same time. In our center, 
we set specialized transplant clinic and establish a complete follow-up procedure 
(Figure 6). The patients should follow the standard follow-up program in the 
absence of complications, including outpatient frequency and inspection items of 
follow-up (see Table 4) [113, 114]. Because exceeding or insufficient immunosup-
pressive agent has a negative effect on graft function, its concentration must be 
monitored regularly (see Table 5). In addition, there is a big problem in China now 
that all the candidates and recipients are lack of health education related with organ 
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transplantation, which lead to many problems of long survival and better quality of 
life. Our center is aware of it and gives the patients regular health education during 
follow-up through PPT, video and handbook, etc. [115, 116].
Figure 6. 
Follow-up procedure after liver transplantation.












































HBsAg (for chronic hepatitis B patients) Once a month Once half year
HBV-DNA (for chronic hepatitis B 
patients)
Once a month Once half year
HCV-DNA Once a month Once half year
AFP (for hepatocellular carcinoma 
patients)
Once a month Once half year
Color ultrasound of transplanted liver Once a month Once half year
Chest film or lung CT Once a month Once half year
CT and MRCP Once 3 months Once half year
Abbreviation: m, month; post-LT, post liver transplantation.
Table 4. 
Frequency and inspection items of follow-up.
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As is well known, the success of liver transplant surgery only means the begin-
ning of a new life for patients. The long-term survival of liver transplant recipients 
depends not only on the surgical skills of surgeons, but also on the high quality and 
efficient follow-up after liver transplantation. With the increase in the number of 
liver transplantation and the application of CLTR, the experts and scholars in China 
will have more experience to help the patients benefit from liver transplantation.
9. Conclusion and future perspectives
After decades of efforts, the liver transplantation in Mainland China has made 
many achievements. The number of cases has ranked second in the world, and the 
quality and survival rate are no different from those of advanced countries; since 
2010, China’s organ donation work has been gradually carried out, and the source of 
liver transplant donors has transitioned from relying on judicial channels to DCDs 
and relative living donors. Before 2015, DCD work has not been widely carried out 
in the country. For some time, due to the shortage of donors, the proportion of 
living relatives has increased significantly (Figures 7 and 8), but with the develop-
ment of DCD work, DCD has become the main source of liver, which better allevi-
ated the problem of organ shortage, meanwhile many shortcoming and problems 
have been exposed in the DCD era.
(1) The main primary disease of liver transplantation in current China is still 
HBV-related disease. China is a large HBV country, and patients requiring liver 
transplantation are increasing year by year. Although DCD donors alleviate 
the shortage of donors to a certain extent, it is necessary for Chinese health 
management departments to pay more attention to the prevention and treat-
ment of HBV and related research work. For transplant experts, more work 
and research is needed on HBV treatment and prevention of recurrence before 
and after transplantation.
(2) The proportion of liver cancer liver transplants in China is high (Figures 9 
and 10). How to develop a liver transplantation standard suitable for liver 
cancer in China, how to reduce the recurrence of liver cancer after transplanta-
tion, prolong the survival time, and how to effectively combine with immuno-
suppressant are also problems faced by Chinese physicians.
(3) Legal regulations are not yet complete. China has not established a brain death 
law, and the relevant transplant laws and regulations are also quite lacking. 
1 D–1 Mpost-LT 1–3 Mpost-LT 3–12 Mpost-LT >12 Mpost-LT
Fk506 C0
(ng/mL)
8–10 6–8 6–8 5–7
CSA C0
(ng/mL)
200–350 150–300 100–250 >50
CSA C2
(ng/mL)
1000–1500 800–1200 600–1000 >400
SIR C0
(ng/mL)
5–8 4–8 4–8 3–6
Abbreviation: C0, the minimal concentration; C2, peak plasma concentration.
Table 5. 
Immunosuppressive agents concentration based on postoperative time.
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Figure 7. 
Proportion of living donor liver transplantation (data from CLTR).
Figure 8. 
The categories of living donors (data from CLTR).
Figure 9. 
2010–2017 Primary disease statistics of DCD liver transplant recipients (data from CLTR).
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The corresponding management system is still not perfect. The Chinese 
government and transplant experts are also constantly exploring and working 
hard on these issues.
(4) DCD-related work needs to be strengthened. China’s contribution rate per mil-
lion populations is very low, only about three cases per million people. In order 
to better carry out DCD work, it is necessary to increase the positive publicity 
of organ donation, further improve the donation, acquisition and distribution 
system, and establish effective services for transplant-related institutions. 
These are issues that China still needs to solve.
China’s liver transplantation is facing enormous challenges and opportunities. 
It not only faces legal issues, sociology, ethics, and many other issues in donor 
donation, but also requires surgeons to refine and continuously improve surgical 
methods. More related researches needed to be done by transplant scholars. The 
entry criteria for liver transplant recipients and the induction of human immune 
tolerance in accordance with China’s national conditions also depend on further 
research by domestic transplant workers, and the solution to these problems will 
be tortuous and difficult. We believe that through the long-term joint efforts of the 
Chinese transplanting colleagues, China’s liver transplantation will have a brighter 
future.
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